Stimulation method for treatment of dermatological conditions
One aspect of the present disclosure relates to a method for modulating, suppressing or preventing a dermatological disorder in a subject. One step of the method can include positioning at least one electrode on or proximate to at least one of a sphenopalatine ganglion (SPG), a sphenopalatine nerve (SN), a vidian nerve (VN), a greater petrosal nerve (GPN), a deep petrosal nerve (DPN), or a branch thereof, of the subject. Next, the at least one electrode can be activated to apply an electrical signal to at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof.
1. A method for modulating, suppressing or preventing a dermatological disorder in a subject, the method comprising the steps of:
receiving at least one electrode on or proximate to at least one of a sphenopalatine ganglion (SPG), a sphenopalatine nerve (SN), a vidian nerve (VN), a greater petrosal nerve (GPN), a deep petrosal nerve (DPN), or a branch thereof, of the subject, wherein the dermatological disorder is mediated by autonomic or neurological dysfunction; and
activating the at least one electrode, wherein the at least one electrode is confiured to apply an electrical signal to at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof to modulate, suppress, or prevent the dermatological disorder in the subject.
2. The method of claim 1 , wherein application of the electrical signal disrupts nerve signal generation in, or transmission through, at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof.
3. The method of claim 1 , wherein the at least one electrode is received without penetrating the cranium, into the pterygopalatine fossa so that the at least one electrode is positioned on or proximate to at least one of the SPG, the SN, the VN, or the branch thereof.
4. The method of claim 1 , wherein the at least one electrode is received without penetrating the palate and without entering into the nasal cavity.
5. The method of claim 1 , wherein the activating step generates heat insufficient to cause a lesion on at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof.
6. The method of claim 1 , further including the step of adjusting the electrical signal without requiring an invasive procedure on the subject.
7. The method of claim 1 , wherein the at least one electrode is received proximate to the GPN, the DPN, or a branch thereof, via an intravascular route.
8. A method for modulating, suppressing or preventing rosacea in a subject, the method comprising the steps of:
receiving at least one electrode on or proximate to at least one of a SPG, a SN, a VN, a GPN, a DPN, or a branch thereof, of the subject; and
activating the at least one electrode, wherein the at least one electrode is configured to apply an electrical signal to at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof to modulate, suppress, or prevent the rosacea in the subject, wherein the rosacea is mediated by autonomic or neurological dysfunction.
9. The method of claim 8 , wherein the rosacea is selected from the group consisting of erythmatotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea and ocular rosacea.
10. The method of claim 8 , wherein the at least one electrode is received without penetrating the cranium, into the pterygopalatine fossa so that the at least one electrode is positioned on or proximate to at least one of the SPG, the SN, the VN, or the branch thereof.
11. The method of claim 8 , wherein the at least one electrode is received without penetrating the palate and without entering into the nasal cavity.
12. The method of claim 8 , wherein the activating step generates heat insufficient to cause a lesion on at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof.
13. The method of claim 8 , wherein the at least one electrode is received proximate to the GPN, the DPN, or a branch thereof, via an intravascular route.
14. A method for modulating, suppressing or preventing a medical condition in a subject, the method comprising the steps of:
receiving at least one electrode on or proximate to at least one of a SPG, a SN, a VN, a GPN, a DPN, or a branch thereof, of the subject; and
activating the at least one electrode, wherein the at least one electrode is configured to apply an electrical signal to at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof to modulate, suppress, or prevent the medical condition in the subject;
wherein the medical condition is at least one of erythrophobia and facial hyperhidrosis;
wherein the medical condition is mediated by autonomic or neurological dysfunction;
wherein the at least one electrode is received without penetrating the palate and without entering into the nasal cavity.
15. The method of claim 14 , wherein application of the electrical signal disrupts nerve signal generation in, or transmission through, at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof.
16. The method of claim 14 , wherein the at least one electrode is received without penetrating the cranium, into the pterygopalatine fossa so that the at least one electrode is positioned on or proximate to at least one of the SPG, the SN, the VN, or the branch thereof.
17. The method of claim 14 , wherein the at least one electrode is received proximate to the GPN, the DPN, or a branch thereof, via an intravascular route.